Replies to post #3432 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

yes. 100%.if ask me, there is no chance of fully diluted the coming years, even not 50% imo, but even w/fully diluted(warrants) cap is still a joke relating this : "KIT-302, has blockbuster peak annual sales potential in the United States alone": http://www.analystratings.com/2016/02/16/rodman-renshaw-initiates-a-buy-rating-on-kitov-pharmceuticals/431432/

Fully diluted it's still only a 40m and change company with 20m+ in cash.current cap is about 20m a/o today. zero debt and over 20m in Cash.

will be better to Treat them like a regular stock instead of exercising for several reasons:

1. Fees and lock-up period if you exercise.

2. Warrants not “in the money”. if warrants will not get a premium this might continue in the future as well.

3. Warrants can offer significant gains to an investor. If commons are trading $10 (Rodman & Renshaw PT),those Warrants will be trading at least $6.13 (10-3.87 ), 8 times investment return vs 3 times+ investment return if you own common shares.

4.The warrants exercisable at 3.87, Expired almost 5 years out on 11/19/2020 and i find no reason to exercise them the upcoming year due KIT-302 gonna hit the market in 2017 as represented by the company.this also a Potential takeover target by Pfizer or another big Pharma. imo